edelfosine has been researched along with Leukemia in 29 studies
edelfosine: RN given refers to parent cpd
edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.
1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| " A survey of the in vitro activity of racemic 1-octadecyl-2-methoxy-glycero-3 phosphorylcholine on in vitro clonogenicity in soft agar and tritiated thymidine incorporation was conducted on bone marrow specimens from a series of patients with acute myelogenous leukemia (AML) and chronic myelocytic leukemia (CML) and hematologically normal individuals." | 3.67 | The effect of alkyl-lysophospholipids on tritiated thymidine incorporation and clonogenicity in vitro of normal and leukemic human cells. ( Long, RC; Somberg, LB; Vogler, WR; Whigham, EA; Winton, EF, 1984) |
| "440 and the ether-linked lipoidal amine CP-46,665 on tritiated thymidine uptake and trypan blue dye exclusion were tested in vitro in various freshly explanted cell samples from human nonneoplastic bone marrow and human leukemias." | 3.67 | Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro. ( Berdel, WE; Eibl, H; Fink, U; Fromm, M; Jehn, U; Rastetter, J; Reichert, A; Schick, HD; Ulm, K; Unger, C, 1987) |
| " Encapsulation of edelfosine (ET) in lipid nanoparticles (LNs) improves its oral bioavailability and decreases its toxicity." | 1.39 | Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. ( Blanco-Príeto, MJ; Estella-Hermoso de Mendoza, A; Lasa-Saracíbar, B; Mollinedo, F; Odero, MD, 2013) |
| "Edelfosine treatment recruited Hsp90, c-Jun N-terminal kinase (JNK) and apoptotic molecules in lipid rafts, but not the JNK regulators apoptosis signal-regulating kinase 1 (ASK1) and Daxx, or the survival signaling molecules extracellular signal-regulated kinase (ERK) and Akt." | 1.35 | Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. ( Gajate, C; González-Camacho, F; Mollinedo, F; Nieto-Miguel, T, 2008) |
| " All the mice given cells not treated with ALP succumbed to leukemia, whereas there was a dose-response increase in survival in those given ALP treated cells." | 1.28 | Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results. ( Berdel, WE; Glasser, L; Okamoto, S; Olson, AC; Vogler, WR, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (34.48) | 18.7374 |
| 1990's | 14 (48.28) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lasa-Saracíbar, B | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Mollinedo, F | 5 |
| Odero, MD | 1 |
| Blanco-Príeto, MJ | 1 |
| Nieto-Miguel, T | 2 |
| Gajate, C | 4 |
| González-Camacho, F | 1 |
| Vogler, WR | 10 |
| Whigham, EA | 1 |
| Somberg, LB | 1 |
| Long, RC | 1 |
| Winton, EF | 3 |
| Heesbeen, EC | 1 |
| Rijksen, G | 1 |
| van Heugten, HG | 1 |
| Verdonck, LF | 1 |
| Berdel, WE | 12 |
| Berkovic, D | 1 |
| Berkovic, K | 1 |
| Fleer, EA | 2 |
| Eibl, H | 5 |
| Unger, C | 3 |
| Shoji, M | 4 |
| Fukuhara, T | 1 |
| Olson, AC | 5 |
| Hajdu, J | 2 |
| Raynor, R | 1 |
| Kuo, JF | 3 |
| Yamazaki, T | 1 |
| Sieber, F | 1 |
| Geller, RB | 1 |
| Brochstein, JA | 1 |
| Beveridge, RA | 1 |
| Dalton, WS | 1 |
| Miller, KB | 1 |
| Lazarus, HM | 1 |
| Santos-Beneit, AM | 1 |
| Macho, A | 1 |
| Lazaro, Md | 1 |
| Hernandez-De Rojas, A | 1 |
| Modolell, M | 1 |
| Muñoz, E | 1 |
| Min, WS | 1 |
| Park, HM | 1 |
| Han, CH | 1 |
| Park, JW | 1 |
| Kim, CC | 1 |
| Kim, DJ | 2 |
| Okamoto, S | 4 |
| Heffner, LT | 1 |
| Gordon, DS | 1 |
| Raynor, RL | 1 |
| Nomura, H | 1 |
| Glasser, L | 1 |
| Santos, GW | 1 |
| Colvin, OM | 1 |
| Lai, CS | 1 |
| Joseph, J | 1 |
| Shih, CC | 1 |
| Chabot, MC | 1 |
| Wykle, RL | 1 |
| Modest, EJ | 1 |
| Daniel, LW | 1 |
| Oishi, K | 1 |
| Zheng, B | 1 |
| White, JF | 1 |
| Fink, U | 3 |
| Rastetter, J | 3 |
| Danhauser, S | 1 |
| Schick, HD | 2 |
| Fromm, M | 2 |
| Reichert, A | 2 |
| Busch, R | 1 |
| Jehn, U | 1 |
| Ulm, K | 1 |
| Kötting, J | 1 |
| Bartsch, HH | 1 |
| Nagel, GA | 1 |
| Pfizenmaier, K | 1 |
| Roos, G | 1 |
2 reviews available for edelfosine and Leukemia
| Article | Year |
|---|---|
Ether lipids in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Drug Evaluation; Drug Evaluation, Precl | 1990 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Ch | 1986 |
6 trials available for edelfosine and Leukemia
| Article | Year |
|---|---|
Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1993 |
A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow.
Topics: Adolescent; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Combi | 1996 |
Alkyl-lysophospholipid purging for autologous bone marrow transplantation in acute leukemia in second or subsequent remission after extramedullary relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Humans; | 1992 |
[Purging of leukemic cells using alkyllysophospholipid].
Topics: Antineoplastic Agents; Bone Marrow Purging; Humans; Leukemia; Phospholipid Ethers | 1992 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Ch | 1986 |
Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; | 1987 |
22 other studies available for edelfosine and Leukemia
| Article | Year |
|---|---|
Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Chemistry, Physical; Drug Delivery Sys | 2013 |
Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Endoplasmic Reticulum; fas Receptor; HeLa Cel | 2006 |
Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy.
Topics: Antineoplastic Agents; Apoptosis; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; JNK Mitogen-Activa | 2008 |
The effect of alkyl-lysophospholipids on tritiated thymidine incorporation and clonogenicity in vitro of normal and leukemic human cells.
Topics: Bone Marrow Cells; Cell Line; Circadian Rhythm; Colony-Forming Units Assay; Humans; Leukemia; Lysoph | 1984 |
Influence of serum levels on leukemic cell destruction by the ether lipid ET-18-OCH3.
Topics: Antineoplastic Agents; Biological Factors; Bone Marrow Cells; Bone Marrow Purging; Cell Division; Ce | 1995 |
Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines.
Topics: Antineoplastic Agents; Cell Division; Cell Membrane; Cytosol; Diglycerides; Dose-Response Relationsh | 1994 |
Different mechanisms of inhibition by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony-stimulating factor binding to human leukemic cell lines.
Topics: Antineoplastic Agents; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Iodine Radioisotope | 1994 |
Structure-function relationships of alkyl-lysophospholipid analogs in selective antitumor activity.
Topics: Antineoplastic Agents; Cell Division; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Hu | 1993 |
The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells.
Topics: Animals; Antineoplastic Agents; Blood Component Removal; Cell Death; Combined Modality Therapy; Drug | 1997 |
Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; DNA Fragmentation; Enzyme | 2000 |
The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells.
Topics: Apoptosis; beta-Cyclodextrins; Cell Membrane; Centrifugation, Density Gradient; Cholesterol; Cyclode | 2001 |
Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
Topics: Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Colony-Forming Units Assay; | 1992 |
Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid.
Topics: Adolescent; Adult; Antineoplastic Agents; Blood Platelets; Bone Marrow; Bone Marrow Cells; Bone Marr | 1992 |
Comparison of selective cytotoxicity of alkyl lysophospholipids.
Topics: Antineoplastic Agents; Cell Survival; Hematopoietic Stem Cells; Humans; Leukemia; Phospholipid Ether | 1991 |
Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Topics: Acute Disease; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplan | 1990 |
Molecular dynamics of antitumor ether-linked phospholipids in model membranes: a spin-label study.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; DNA; Electron Spin Resonance Spectroscopy | 1989 |
Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Leukemia; Membrane Lipids; Phosphol | 1989 |
Inhibition of Na,K-ATPase and sodium pump by anticancer ether lipids and protein kinase C inhibitors ET-18-OCH3 and BM 41.440.
Topics: Animals; Antineoplastic Agents; Cell Membrane; Cerebral Cortex; Erythrocytes; Humans; Leukemia; Lyso | 1988 |
Structure-cytotoxicity studies on alkyl lysophospholipids and some analogs in leukemic blasts of human origin in vitro.
Topics: Antineoplastic Agents; Cell Survival; Cytotoxins; Glyceryl Ethers; Humans; Leukemia; Lysophospholipi | 1987 |
Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Survival; Cytotoxins; Humans; Leukemia; | 1987 |
Sensitivity of leukemia cell lines to cytotoxic alkyl-lysophospholipids in relation to O-alkyl cleavage enzyme activities.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Cell Survival; Dose-Response Relationship, | 1987 |
Sensitivity of human hematopoietic cell lines to an alkyl-lysophospholipid-derivative.
Topics: Cell Cycle; Cell Division; Cell Line; Cell Survival; DNA, Neoplasm; Hematopoietic Stem Cells; Humans | 1986 |